

WORKSHOP





G DICEMBRE 2024 WORKSHOP 2024


Does the perfect resection & histology report exist? The pathologist's perspective

PAOLA CASSONI









9 PREVENZIONE SERENAS DICEMBRE L'OGGI E IL DOMANI 2024 WORKSHOP 2024

SCRLs measuring less than 10mm (<10mm)

- 90% of lesions identified during screening colonoscopy
- Cold Snare Polipectomy (CSP) > Hot Snare Polipectomy (HSP)*

* No significant difference between the two techniques in terms of incomplete resection rate (IRR), but significant increase in procedure time and incidence of adverse events (AEs) in patients undergoing HSP compared to CSP ^{14–16}

SCRLs <3mm: CSP > Cold Biopsy Forceps (CBF)**


Courtesy of A.Mussetto

** CBF may be an alternative in cases where CSP is technically challenging ^{2,3}

Pathologist issue:
✓ Impossible to define specimen orientation & margins in CSP
✓ Endoscopist should orient/ink the specimen








Courtesy of A.Mussetto


Pathologist issue:


- ✓ Possible fragmentation & stalk retraction after FF
- ✓ Keep attention to correct orientation for paraffin inclusion
- \checkmark Keep attention to correct interpretation of dystopic fields (cd Pseudoinvasion)






Orientation & stalk retraction artifacts





Dystopic fields (cd Pseudoinvasion)





✓ What about **pitfalls**?


Pseudoinvasion/ epithelial misplacement (EM) versus real SM invasion


What to look for in order to recognise epithelial misplacement

Guidance


Bowel cancer screening: pathology guidance on reporting lesions Updated 31 May 2021

- Epithelial 'differentiation'
- Lamina propria accompaniment
- Accompaniment by non-adenomatous epithelium
- •Haemosiderin deposition
- Mucosal prolapse changes
- Mucus cysts
- Continuity with surface adenomatous component
- Budding
- Desmoplastic reaction to glands
 Lymphatic and/or vascular invasion









Pathologist issue:
 ✓ Impossible to define specimen orientation & margins in pCSR
 ✓ Endoscopist should orient/ink the specimen

Non-pedunculated SCRLs measuring 20 mm and

above (≥20mm) without features of SMIC

- Adequate characterization according to internationally validated classifications using high-resolution white light and chromoendoscopy should be recommended
- For SCRLs proximal to the rectum and at low risk of SMIC (i.e JNET2a), either en bloc or piecemeal resection may be performed*,**

Courtesy of A.Mussetto


*In the case of piecemeal resection, it is recommended to resect the lesion in as few pieces as possible and to complete the procedure with thermal ablation of the margin, ** pCSR could be considered *for SSLs* ≥20mm without dysplasia and carefully selected non-pedunculated adenomas measuring between 10-19mm in the right colon and/or in unfit patients to reduce the risk of peri-procedural and late complications

 For SCRLs in the rectum with a low risk of SMIC (JNET2a), en bloc resection should be preferred if feasible (i.e en bloc EMR or ESD)

Pathologist issue:

- \checkmark Impossible to define margins in piecemeal resections
- ✓ Eventual limitation in defining SMI
- ✓ Endoscopist should orient/ink the specimen






Pathologist issue:

- \checkmark difficulties in defining specimen orientation can limit 1)
- \checkmark fragmentation does not allow 2) and impacts on 3)
- ✓ Endoscopist orient ation of fragments helps



Histologic Staging and Piecemeal Resection



ORIENTATION OF THE MICROTOMY PLANE "... Pieces should be oriented by the Endoscopist with their submucosal side facing the plate..."










[Quirke, Risio , Lambet, Vieth 2010]

Neither the Kikuchi (for sessile lesions) nor Haggitt (for polypoid tumors) are easy to use in practice. The depth and the width of invasion provides a more objective measure.

Each classification has advantages and disadvantages.


All approaches need to be evaluated on large series from screening programmes to derive evidence-based recommendations.





Positive surgical margin is an adverse prognostic factor in pT1 CRC, for the presence of **residual disease** and/or for **LNM**

PREVENZIONE SERENA



¹ Positive vertical margin is defined as carcinoma exposed at the submucosal margin of the resected specimen by JSCCR guidelines. ². Positive resection margin (<1 mm) is considered only a risk for local recurrence in ESMO guidelines. Its recommended management comprises additional excision or local surveillance.

MULTIDISCIPLINARY DISCUSSION

Review > J Clin Pathol. 2024 Mar 20;77(4):225-232. doi: 10.1136/jcp-2023-208803.

Risk assessment in pT1 colorectal cancer

Emma Jane Norton¹, Adrian C Bateman²

The nature of histopathological examination means that microscopic features are commonly more difficult to assess in routine diagnostic practice than published criteria may initially suggest. Factors hampering histopathological examination include sampling variability, tangential cutting and other difficulties with orientation, fragmentation, diathermy artefact and tumour-related issues. While

In our experience, the ability to quantify LNM risk in this setting is valuable during multidisciplinary team (MDT) discussions and clinician-patient interactions. Where relevant, the *Royal College of* Endoscopic submucosal dissection for superficial gastrointestinal lesions: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2022

ALWAYS!!!

ESGE recommends that when there is a diagnosis of lymphovascular invasion, or deeper infiltration than sm1, or positive vertical margins, or undifferentiated tumor, or, for colorectal lesions, budding grade 2 or 3, this should be considered a high risk (noncurative) resection, and complete staging and strong consideration for additional treatments should be considered on an individual basis in a multidisciplinary discussion.

Practical issue:

At the end of the histology report add the need of MDT

TO THE BEST OF OUR KNOWLEDGE: Check list and standardized report for pT1 CRC according to guidelines

Materiale inviato : Polipo Sessile di 15 mm del retto.

Notizie Cliniche : Polipo Sessile di 15 mm del retto.

Descrizione Macroscopica : Formazione polipoide sessile di cm 1,5, sezionata a metà.

Descrizione Microscopica :

Idoneità ai fini di eventuali analisi molecolari: Campione ADEGUATO (Criteri richiesti >50% e >100 cellule tumorali selezionate, sec linee guida aggiornamento AIOM-SIAPEC-IAP 10-11-2010), blocchetto A1, selezione tumorale: sì.

Eseguite indagini immunoistochimiche con anticorpi per:

- MLH-1 (Ac. monoclonale Leica, clone ES05);
- PMS-2 (Ac. monoclonale Leica, clone EP51);
- MSH-2 (Ac. monoclonale Leica, clone 79H11);
- MSH-6 (Ac. monoclonale Leica, clone EP49).

Diagnosi:

ADENOCARCINOMA DI BASSO GRADO INFILTRANTE LA TONACA SOTTOMUCOSA, INSORTO SU ADENOMA TUBULO-VILLOSO CON DISPLASIA DI ALTO GRADO (c.d. ADENOMA CANCERIZZATO).

Staging sec VIII edizione UICC, 2017: pT1.

SEDE DELLA NEOPLASIA: Retto

TIPO DI NEOPLASIA: Adenocarcinoma senza componente mucinosa GRADO ISTOLOGICO: Basso grado TIPO DI INVASIONE NEOPLASTICA: Infiltrativa PROFONDITA' DI INVASIONE: Tumore che invade la sottomucosa (pT1) LIVELLO DI INVASIONE DELLA SOTTOMUCOSA: Profondità di invasione della sottomucosa: 1.5 mm Ampiezza di invasione sottomucosa: 3 mm INVASIONE VASCOLARE EMATICA O LINFATICA: Non evidente sulle sezioni esaminate INVASIONE PERINEURALE: Non evidente sulle sezioni esaminate BUDDING TUMORALE: BD1 (0-4 buds)

INFILTRATO LINFOCITARIO PERINEOPLASTICO: moderatamente rappresentato MARGINI DI RESEZIONE: Indenni (distanza minima dal margine profondo 2 mm).

Necessaria discussione multidisciplinare.

Espressione immunoistochimica delle proteine del mismatch repair (MMR)

Le cellule della neoplasia presentano espressione immunoistochimica (++) per la proteina codificata dal gene **MLH-1** (controllo interno positivo).

PREVENZIONE S E R E N A

Le cellule della neoplasia presentano espressione immunoistochimica (++) per la proteina codificata dal gene **PMS2** (controllo interno positivo).

Le cellule della neoplasia presentano espressione immunoistochimica (++) per la proteina codificata dal gene **MSH-2** (controllo interno positivo).

Le cellule della neoplasia presentano espressione immunoistochimica (++) per la proteina codificata dal gene **MSH-6** (controllo interno positivo).

CONCLUSIONI

L'espressione immunoistochimica delle proteine MMR risulta compatibile con uno stato di stabilità dei microsatelliti (MSS).